Welcome

Risdiplam: FIREFISH part 2 efficacy and safety in infants with type 1 SMA

Risdiplam: Update on clinical development program

OCREVUS: Long-term data on key markers of disability progression in MS Shorter infusion (ENSEMBLE PLUS) data and regulatory update

Q&A

Karl Mahler, Head of Investor Relations and Roche Group Planning

Prof. Laurent Servais, MDUK Oxford Neuromuscular Center, Department of Paediatrics, University of Oxford, UK

Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development